Glucosamine and Chondroitin Effects (GLANCE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT01682694
First received: September 4, 2012
Last updated: May 23, 2014
Last verified: May 2014

September 4, 2012
May 23, 2014
September 2012
August 2013   (final data collection date for primary outcome measure)
hsCRP [ Time Frame: 1 year ] [ Designated as safety issue: No ]
hsCRP is a biomarker of systemic inflammation
Same as current
Complete list of historical versions of study NCT01682694 on ClinicalTrials.gov Archive Site
untargeted (exploratory) serum metabolomics (differences in small molecule abundance ratios) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
The mechanisms of action of glucosamine and chondroitin are currently unknown. Untargeted metabolomic assays of serum will be undertaken for exploratory analyses of potential effects of glucosamine and chondroitin. Significant differences in abundance ratios of small molecules between the intervention and placebo will be reported.
Same as current
Not Provided
Not Provided
 
Glucosamine and Chondroitin Effects
Glucosamine and Chondroitin Effects

A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected by a reduction in serum C-reactive protein.

Use of glucosamine and chondroitin have been associated with reduced cancer and overall mortality. The aim of this study is to determine whether a common starting dose of glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic inflammation as reflected by a reduction in high sensitivity C-reactive protein.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Inflammation
  • Dietary Supplement: Glucosamine and Chondroitin
    Glucosamine (1500 mg) and Chondroitin (1200 mg)
    Other Name: Nutramax
  • Dietary Supplement: placebo
  • Experimental: Glucosamine and Chondroitin
    Glucosamine and Chondroitin
    Intervention: Dietary Supplement: Glucosamine and Chondroitin
  • Placebo Comparator: Placebo
    Inactive ingredients
    Intervention: Dietary Supplement: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
August 2013
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy
  • Overweight (body mass index kg/m2 (BMI) between 25 and 32.5)
  • Non-smoking men and women
  • Aged 20-55y

Exclusion Criteria:

  • Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or inflammatory conditions (including autoimmune and inflammatory diseases)
  • Pregnancy or lactation
  • Currently on a weight-loss diet
  • BMI (body mass index) < 25 or > 30
  • Alcohol intake of greater than 2 drinks/day
  • Current use of prescription or over-the-counter medications, (Excluding oral contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more than 2 days per week
  • Abnormal renal, liver or metabolic test
  • Inability to swallow pills
  • Known allergy to shellfish
  • Not willing to take pills made from shellfish or animal sources
  • Intention to relocate out of study area within next 4 months
Both
20 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01682694
7798
No
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
Not Provided
Not Provided
Fred Hutchinson Cancer Research Center
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP